ID   PLK4_HUMAN              Reviewed;         970 AA.
AC   O00444; B2RAL0; B7Z837; B7Z8G7; Q8IYF0; Q96Q95; Q9UD84; Q9UDE2;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-NOV-2007, sequence version 3.
DT   02-NOV-2010, entry version 92.
DE   RecName: Full=Serine/threonine-protein kinase PLK4;
DE            EC=2.7.11.21;
DE   AltName: Full=Polo-like kinase 4;
DE            Short=PLK-4;
DE   AltName: Full=Serine/threonine-protein kinase 18;
DE   AltName: Full=Serine/threonine-protein kinase Sak;
GN   Name=PLK4; Synonyms=SAK, STK18;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS THR-232 AND
RP   ASP-830.
RC   TISSUE=Lung;
RA   Karn T., Holtrich U., Wolf G., Hock B., Strebhardt K.,
RA   Ruebsamen-Waigmann H.;
RT   "Human SAK related to the PLK/polo family of cell cycle kinases shows
RT   high mRNA expression in testis.";
RL   Oncol. Rep. 4:505-510(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PHOSPHORYLATION BY TEC, AND
RP   VARIANTS THR-232 AND ASP-830.
RC   TISSUE=Blood;
RX   MEDLINE=21486437; PubMed=11489907; DOI=10.1074/jbc.M106249200;
RA   Yamashita Y., Kajigaya S., Yoshida K., Ueno S., Ota J., Ohmine K.,
RA   Ueda M., Miyazato A., Ohya K., Kitamura T., Ozawa K., Mano H.;
RT   "Sak serine-threonine kinase acts as an effector of Tec tyrosine
RT   kinase.";
RL   J. Biol. Chem. 276:39012-39020(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND
RP   VARIANTS THR-232 AND ASP-830.
RC   TISSUE=Testis, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 134-196.
RX   PubMed=8260651; DOI=10.1006/smim.1993.1041;
RA   Mills G.B., Schmandt R., Gibson S., Leung B., Hill M., May C.,
RA   Shi Y.F., Branch D.R., Radvanyi L., Truitt K.E., Imboden J.;
RT   "Transmembrane signaling by the interleukin-2 receptor: progress and
RT   conundrums.";
RL   Semin. Immunol. 5:345-364(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 135-196.
RC   TISSUE=Mammary carcinoma;
RX   MEDLINE=92165426; PubMed=1311287; DOI=10.1002/ijc.2910500419;
RA   Lehtola L., Partanen J., Sistonen L., Korhonen J., Warri A.,
RA   Harkonen P., Clarke R., Alitalo K.;
RT   "Analysis of tyrosine kinase mRNAs including four FGF receptor mRNAs
RT   expressed in MCF-7 breast-cancer cells.";
RL   Int. J. Cancer 50:598-603(1992).
RN   [7]
RP   FUNCTION.
RX   PubMed=16326102; DOI=10.1016/j.cub.2005.11.042;
RA   Bettencourt-Dias M., Rodrigues-Martins A., Carpenter L.,
RA   Riparbelli M., Lehmann L., Gatt M.K., Carmo N., Balloux F.,
RA   Callaini G., Glover D.M.;
RT   "SAK/PLK4 is required for centriole duplication and flagella
RT   development.";
RL   Curr. Biol. 15:2199-2207(2005).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-154.
RX   PubMed=16244668; DOI=10.1038/ncb1320;
RA   Habedanck R., Stierhof Y.-D., Wilkinson C.J., Nigg E.A.;
RT   "The Polo kinase Plk4 functions in centriole duplication.";
RL   Nat. Cell Biol. 7:1140-1146(2005).
RN   [9]
RP   INDUCTION BY TP53.
RX   PubMed=15967108; DOI=10.1593/neo.04325;
RA   Li J., Tan M., Li L., Pamarthy D., Lawrence T.S., Sun Y.;
RT   "SAK, a new polo-like kinase, is transcriptionally repressed by p53
RT   and induces apoptosis upon RNAi silencing.";
RL   Neoplasia 7:312-323(2005).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17681131; DOI=10.1016/j.devcel.2007.07.002;
RA   Kleylein-Sohn J., Westendorf J., Le Clech M., Habedanck R.,
RA   Stierhof Y.-D., Nigg E.A.;
RT   "Plk4-induced centriole biogenesis in human cells.";
RL   Dev. Cell 13:190-202(2007).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF LYS-41 AND THR-170.
RX   PubMed=18239451;
RA   Bonni S., Ganuelas M.L., Petrinac S., Hudson J.W.;
RT   "Human Plk4 phosphorylates Cdc25C.";
RL   Cell Cycle 7:545-547(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-401; SER-421; SER-499;
RP   SER-592; SER-671 AND SER-817, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   FUNCTION, AND MUTAGENESIS OF LYS-41 AND THR-170.
RX   PubMed=19164942;
RA   Petrinac S., Ganuelas M.L., Bonni S., Nantais J., Hudson J.W.;
RT   "Polo-like kinase 4 phosphorylates Chk2.";
RL   Cell Cycle 8:327-329(2009).
RN   [14]
RP   INDUCTION.
RX   PubMed=19454482; DOI=10.1242/jcs.036715;
RA   Kuriyama R., Bettencourt-Dias M., Hoffmann I., Arnold M., Sandvig L.;
RT   "Gamma-tubulin-containing abnormal centrioles are induced by
RT   insufficient Plk4 in human HCT116 colorectal cancer cells.";
RL   J. Cell Sci. 122:2014-2023(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-377; SER-378; SER-401;
RP   TYR-420; SER-421; THR-591; SER-592; SER-665 AND SER-817, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 2-275.
RG   New York structural genomix research consortium (NYSGXRC);
RT   "Crystal structure of PLK4 kinase.";
RL   Submitted (JUN-2009) to the PDB data bank.
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-86; HIS-146; THR-226; THR-232;
RP   LEU-317; ASP-449; SER-519 AND ASP-830.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that plays a central
CC       role in centriole duplication. Able to trigger procentriole
CC       formation on the surface of the parental centriole cylinder,
CC       leading to the recruitment of centriole biogenesis proteins such
CC       as SASS6, CENPJ/CPAP, CP110, CEP135 and gamma-tubulin. When
CC       overexpressed, it is able to induce centrosome amplification
CC       through the simultaneous generation of multiple procentrioles
CC       adjoining each parental centriole during S phase. Its central role
CC       in centriole replication suggests a posible role in tumorigenesis,
CC       centrosome aberrations being frequently observed in tumors. Also
CC       involved in trophoblast differentiation by phosphorylating HAND1,
CC       leading to disrupt the interaction between HAND1 and MDFIC and
CC       activate HAND1. Phosphorylates CDC25C and CHEK2/CHK2.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Homodimer (By similarity).
CC   -!- INTERACTION:
CC       P31947:SFN; NbExp=1; IntAct=EBI-746202, EBI-476295;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, centrosome,
CC       centriole. Nucleus, nucleolus (By similarity). Cleavage furrow.
CC       Note=Associates with centrioles throughout the cell cycle.
CC       According to PubMed:16244668, it is not present at cleavage
CC       furrows.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O00444-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00444-2; Sequence=VSP_038117;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=O00444-3; Sequence=VSP_038116;
CC         Note=No experimental confirmation available;
CC   -!- INDUCTION: Down-regulated in HCT116 colorectal cancer cells,
CC       leading to aberrant centrioles composed of disorganized
CC       cylindrical microtubules and displaced appendages. Down-regulated
CC       by TP53/p53.
CC   -!- PTM: Ubiquitinated; leading to its degradation by the proteasome
CC       (By similarity).
CC   -!- PTM: Tyrosine-phosphorylated by TEC.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. CDC5/Polo subfamily.
CC   -!- SIMILARITY: Contains 1 POLO box domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y13115; CAA73575.1; -; mRNA.
DR   EMBL; AB006972; BAB69958.1; -; mRNA.
DR   EMBL; AK302858; BAH13823.1; -; mRNA.
DR   EMBL; AK303399; BAH13953.1; -; mRNA.
DR   EMBL; AK314238; BAG36907.1; -; mRNA.
DR   EMBL; BC036023; AAH36023.1; -; mRNA.
DR   IPI; IPI00410344; -.
DR   IPI; IPI00944477; -.
DR   IPI; IPI00944493; -.
DR   RefSeq; NP_001177728.1; -.
DR   RefSeq; NP_001177730.1; -.
DR   RefSeq; NP_055079.3; -.
DR   UniGene; Hs.172052; -.
DR   PDB; 3COK; X-ray; 2.25 A; A/B=2-275.
DR   PDBsum; 3COK; -.
DR   ProteinModelPortal; O00444; -.
DR   SMR; O00444; 1-266, 890-964.
DR   IntAct; O00444; 10.
DR   MINT; MINT-1460432; -.
DR   STRING; O00444; -.
DR   PhosphoSite; O00444; -.
DR   PRIDE; O00444; -.
DR   Ensembl; ENST00000270861; ENSP00000270861; ENSG00000142731.
DR   Ensembl; ENST00000507249; ENSP00000423412; ENSG00000142731.
DR   Ensembl; ENST00000513090; ENSP00000427554; ENSG00000142731.
DR   Ensembl; ENST00000514379; ENSP00000423582; ENSG00000142731.
DR   Ensembl; ENST00000515069; ENSP00000421774; ENSG00000142731.
DR   GeneID; 10733; -.
DR   KEGG; hsa:10733; -.
DR   UCSC; uc003ifo.1; human.
DR   CTD; 10733; -.
DR   GeneCards; GC04P128802; -.
DR   H-InvDB; HIX0024544; -.
DR   HGNC; HGNC:11397; PLK4.
DR   HPA; HPA035026; -.
DR   MIM; 605031; gene.
DR   PharmGKB; PA36205; -.
DR   eggNOG; prNOG10220; -.
DR   HOGENOM; HBG315198; -.
DR   HOVERGEN; HBG053617; -.
DR   InParanoid; O00444; -.
DR   OMA; EMPTFLS; -.
DR   OrthoDB; EOG91C9FD; -.
DR   PhylomeDB; O00444; -.
DR   BRENDA; 2.7.11.21; 247.
DR   Reactome; REACT_152; Cell Cycle, Mitotic.
DR   BindingDB; O00444; -.
DR   NextBio; 40744; -.
DR   ArrayExpress; O00444; -.
DR   Bgee; O00444; -.
DR   CleanEx; HS_PLK4; -.
DR   Genevestigator; O00444; -.
DR   GermOnline; ENSG00000142731; Homo sapiens.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:InterPro.
DR   GO; GO:0046601; P:positive regulation of centriole replication; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; TAS:ProtInc.
DR   GO; GO:0060707; P:trophoblast giant cell differentiation; ISS:UniProtKB.
DR   InterPro; IPR020636; Ca/CaM-dep_prot_kinase-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000959; POLO_box_duplicated_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   InterPro; IPR020664; Ser/Thr_prot_kinase_PLK4.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   PANTHER; PTHR22982; Ca/CaM-dep_prot_kinase-like; 1.
DR   PANTHER; PTHR22982:SF50; Ser/Thr_prot_kinase_PLK4; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00659; POLO_box; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50078; POLO_BOX; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; FALSE_NEG.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Cytoskeleton; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Serine/threonine-protein kinase;
KW   Transferase; Ubl conjugation.
FT   CHAIN         1    970       Serine/threonine-protein kinase PLK4.
FT                                /FTId=PRO_0000086567.
FT   DOMAIN       12    265       Protein kinase.
FT   DOMAIN      892    956       POLO box.
FT   NP_BIND      18     26       ATP (By similarity).
FT   ACT_SITE    136    136       Proton acceptor (By similarity).
FT   BINDING      41     41       ATP (Probable).
FT   MOD_RES     377    377       Phosphotyrosine.
FT   MOD_RES     378    378       Phosphoserine.
FT   MOD_RES     401    401       Phosphoserine.
FT   MOD_RES     420    420       Phosphotyrosine.
FT   MOD_RES     421    421       Phosphoserine.
FT   MOD_RES     499    499       Phosphoserine.
FT   MOD_RES     591    591       Phosphothreonine.
FT   MOD_RES     592    592       Phosphoserine.
FT   MOD_RES     665    665       Phosphoserine.
FT   MOD_RES     671    671       Phosphoserine.
FT   MOD_RES     817    817       Phosphoserine.
FT   VAR_SEQ       1     41       Missing (in isoform 3).
FT                                /FTId=VSP_038116.
FT   VAR_SEQ      43     74       Missing (in isoform 2).
FT                                /FTId=VSP_038117.
FT   VARIANT      86     86       Y -> C (in dbSNP:rs34156294).
FT                                /FTId=VAR_041027.
FT   VARIANT     146    146       R -> H (in dbSNP:rs35232579).
FT                                /FTId=VAR_041028.
FT   VARIANT     226    226       A -> T (in dbSNP:rs35448573).
FT                                /FTId=VAR_041029.
FT   VARIANT     232    232       S -> T (in dbSNP:rs3811740).
FT                                /FTId=VAR_019632.
FT   VARIANT     317    317       P -> L (in dbSNP:rs35049837).
FT                                /FTId=VAR_041030.
FT   VARIANT     449    449       N -> D (in dbSNP:rs34906574).
FT                                /FTId=VAR_041031.
FT   VARIANT     519    519       W -> S (in dbSNP:rs56043017).
FT                                /FTId=VAR_041032.
FT   VARIANT     830    830       E -> D (in dbSNP:rs17012739).
FT                                /FTId=VAR_041033.
FT   MUTAGEN      41     41       K->M: Abolishes ability to phosphorylate
FT                                CDC25C and CHEK2/CHK2.
FT   MUTAGEN     154    154       D->A: Catalytically inactive mutant that
FT                                causes some centrosome amplification
FT                                above background levels when
FT                                overexpressed.
FT   MUTAGEN     170    170       T->D: Activating mutant.
FT   CONFLICT     34     34       T -> S (in Ref. 2; BAB69958).
FT   CONFLICT     58     58       Q -> K (in Ref. 1; CAA73575).
FT   CONFLICT    333    333       D -> N (in Ref. 3; BAH13823).
FT   CONFLICT    387    387       S -> R (in Ref. 2; BAB69958).
FT   CONFLICT    692    692       F -> S (in Ref. 3; BAH13823).
FT   CONFLICT    696    696       V -> L (in Ref. 2; BAB69958).
FT   CONFLICT    768    768       Y -> F (in Ref. 1; CAA73575).
FT   CONFLICT    842    842       A -> D (in Ref. 2; BAB69958).
FT   HELIX         2      5
FT   HELIX         9     11
FT   STRAND       12     20
FT   STRAND       22     31
FT   TURN         32     34
FT   STRAND       37     44
FT   HELIX        45     50
FT   HELIX        54     64
FT   STRAND       75     80
FT   STRAND       82     90
FT   HELIX        97    102
FT   HELIX       110    129
FT   HELIX       139    141
FT   STRAND      142    144
FT   STRAND      150    152
FT   HELIX       193    206
FT   HELIX       236    245
FT   HELIX       250    252
FT   HELIX       256    259
FT   TURN        263    265
SQ   SEQUENCE   970 AA;  108972 MW;  4D56F5FD983211A6 CRC64;
     MATCIGEKIE DFKVGNLLGK GSFAGVYRAE SIHTGLEVAI KMIDKKAMYK AGMVQRVQNE
     VKIHCQLKHP SILELYNYFE DSNYVYLVLE MCHNGEMNRY LKNRVKPFSE NEARHFMHQI
     ITGMLYLHSH GILHRDLTLS NLLLTRNMNI KIADFGLATQ LKMPHEKHYT LCGTPNYISP
     EIATRSAHGL ESDVWSLGCM FYTLLIGRPP FDTDTVKNTL NKVVLADYEM PSFLSIEAKD
     LIHQLLRRNP ADRLSLSSVL DHPFMSRNSS TKSKDLGTVE DSIDSGHATI STAITASSST
     SISGSLFDKR RLLIGQPLPN KMTVFPKNKS STDFSSSGDG NSFYTQWGNQ ETSNSGRGRV
     IQDAEERPHS RYLRRAYSSD RSGTSNSQSQ AKTYTMERCH SAEMLSVSKR SGGGENEERY
     SPTDNNANIF NFFKEKTSSS SGSFERPDNN QALSNHLCPG KTPFPFADPT PQTETVQQWF
     GNLQINAHLR KTTEYDSISP NRDFQGHPDL QKDTSKNAWT DTKVKKNSDA SDNAHSVKQQ
     NTMKYMTALH SKPEIIQQEC VFGSDPLSEQ SKTRGMEPPW GYQNRTLRSI TSPLVAHRLK
     PIRQKTKKAV VSILDSEEVC VELVKEYASQ EYVKEVLQIS SDGNTITIYY PNGGRGFPLA
     DRPPSPTDNI SRYSFDNLPE KYWRKYQYAS RFVQLVRSKS PKITYFTRYA KCILMENSPG
     ADFEVWFYDG VKIHKTEDFI QVIEKTGKSY TLKSESEVNS LKEEIKMYMD HANEGHRICL
     ALESIISEEE RKTRSAPFFP IIIGRKPGST SSPKALSPPP SVDSNYPTRE RASFNRMVMH
     SAASPTQAPI LNPSMVTNEG LGLTTTASGT DISSNSLKDC LPKSAQLLKS VFVKNVGWAT
     QLTSGAVWVQ FNDGSQLVVQ AGVSSISYTS PNGQTTRYGE NEKLPDYIKQ KLQCLSSILL
     MFSNPTPNFH
//
